English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 18 May 2020, 13:33 JST
Share:
    

Source: Eisai
Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules
The first OTC product containing the same amount of stomach-protecting teprenone as for medical purposes

TOKYO, May 18, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched New Selbelle Premium Tablets and New Selbelle Premium Fine Granules (both are category-2 OTC drug, "New Selbelle Premium") on May 18, 2020 at pharmacies and drugstores throughout Japan, as a new addition to the Selbelle brand lineup of products which protect and condition the weakened stomach with a gastric mucus barrier.

SEI-I*, which is the value offered by the Selbelle brand, is Eisai's unique concept of increasing gastric mucus to protect the stomach wall while revitalizing the stomach to improve its condition. Stomach ailments, such as indigestion unrelated to overeating and stomach discomfort, prevent the enjoyment of eating on a routine basis. These ailments are thought to be caused by a decrease of mucus in the stomach and stagnation of stomach function that occur with aging.
For the first time in an OTC product, the in-house developed gastric mucus-increasing component 'teprenone' is contained in New Selbelle Premium at the same amount as found in prescription drugs.

The compounding amount of 'teprenone' was increased to 150mg / day for New Selbelle Premium from 112.5 mg / day for the conventional product. In addition, New Selbelle Premium contains two natural extracts that revitalize stomach functions and digestive enzymes that help to digest fat. The effect of SEI-I derived from these ingredients relieves stomach discomfort and restores the joy of eating by energizing the stomach.

As we enter the era of 100 years of life, Eisai considers it very important for all consumers to be able to enjoy their food every day in order to gain contentment in everyday life. With its launch of New Selbelle Premium, Eisai will evoke the joy of eating with the effects of SEI-I, and further respond to the wishes of consumers who want to enjoy their favorite foods through their whole lifetime and to enjoy their meals with precious family and friends.

* SEI-I, which is a registered trademark of Eisai (Registration number: 4983286), implies the idea of reconditioning the declined stomach function to normal.

Contact:
Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
Thursday, 18 April 2024, 10:53 JST
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Wednesday, 17 April 2024, 16:17 JST
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
2024年4月17日 10時00分 JST
エーザイ、抗てんかん剤「フィコンパ(R)」の注射剤を新発売
Wednesday, 3 April 2024, 16:24 JST
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
Monday, 1 April 2024, 9:39 JST
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575